Quarterly report pursuant to Section 13 or 15(d)

Business combinations - Proforma Information (Details)

v3.24.2.u1
Business combinations - Proforma Information (Details) - USD ($)
$ in Thousands
3 Months Ended 5 Months Ended 6 Months Ended 12 Months Ended
Jun. 01, 2023
Jun. 30, 2024
Jun. 30, 2023
May 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Business Acquisition [Line Items]              
Gain on bargain purchase     $ 22,155     $ 22,155  
Share-based compensation expense   $ 3,057 $ 3,837   $ 6,160 5,513  
TCR2 Therapeutics              
Business Acquisition [Line Items]              
Revenue           52,731  
Net loss           (86,202)  
Acquisition-related costs incurred by TCR2           7,700  
Gain on bargain purchase $ 22,049         22,000  
Acquisition-related costs           $ 7,165 $ 7,346
Share-based compensation expense       $ 1,000